Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Comment by Hoover69on Sep 15, 2021 7:35am
99 Views
Post# 33860421

RE:RE:RE:RE:RE:RE:Stop buying Bob Mcwhirters stock picks ...

RE:RE:RE:RE:RE:RE:Stop buying Bob Mcwhirters stock picks ...Candy, here a few more thoughts on this. Both XRX and CMC are highly speculative penny stocks - penny stocks can offer sizeable gains but also come with the risk of losing a significant amount of your investment in a short period of time - they are probably not the place to begin your investing career. You seem to be referencing CMC with your comments on "Table Pounding" - again, no one forced anyone to buy these stocks, let alone watch Market Call on BNN. It can however be a good point of reference for one to get some investing ideas, but again we should do our own research before entering into a transaction. CMC has a Price to Sales ratio of over 58,000 to 1 - a good ratio for an established company is between 1 and 2 - so Cielo screams high risk. In addition, their 52 week low is .055 while the high is $1.65 - again screaming high risk.  Only one analyst covers CMC (target price of about $2.05) so again one can conclude this company is not widely followed so comes with a higher degree of risk. FYI, Apple has 44 analysts following it according to MarketWatch. Investing is very interesting and can be both fun and profitable - but one can also lose money very quickly. I say this from experience as I still have my laminated share certificates for my purchase of 600 shares of Worldwide Interactive over 30 years ago - the broker convinced me I had to buy now as it was going to be a rocket! I lost my entire thousand dollars but it was a great lesson to learn along the way. I did not make the time to do any research but just took his word on things! As Vitalina says, I was a LOSER!  By constrast, if I had purchased Berkshire Hathaway with my thousand dollars, it would be worth about 60,000 today!

All the best going forward Candy.
<< Previous
Bullboard Posts
Next >>